Evidence map›Paper›PMID 42063341›Full record

ArticleDevelopment (Cambridge, England)2026

Multi-dimensional regulation of LIN-28 temporal expression dynamics in the C. elegans heterochronic gene cascade.

Charles Nelson, Victor Ambros

Abstract read
In one paragraph

Article in Development (Cambridge, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Charles NelsonProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.ORCID 0000-0002-9639-2971
Victor AmbrosProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.ORCID 0000-0002-5562-5345

Funding

Genetic control of developmental timingR35GM131741 · NIGMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Victor Ambros · 2019 to 2026
$5.9M
NIH HHS R35GM131741University of Massachusetts Chan Medical School
6 · The paper itself

Abstract

LIN-28 is an evolutionarily conserved RNA-binding protein that is crucial for regulating pluripotency and cell fate determination during animal development. In Caenorhabditis elegans, lin-28 is an integral component of the heterochronic (developmental timing) gene regulatory cascade. Loss-of-function mutations in lin-28 cause precocious cell fate determination during larval development. Previous studies indicate that proper progression of larval stage-specific cell fates relies on the downregulation of LIN-28, which is negatively regulated by the lin-4 microRNA through complementary sequences in the lin-28 3' untranslated region (UTR). This study employs CRISPR/Cas9 editing of the endogenous lin-28 locus to demonstrate that developmental downregulation of LIN-28 involves multiple inputs, including the action of the let-7 family and lin-4 microRNAs via adjacent complementary sites in the lin-28 3' UTR, along with post-translational inhibition of LIN-28 by the lep-5 long non-coding RNA, collectively accounting for nearly all LIN-28 repression. Additionally, systematic testing of truncations of the lin-28 3' UTR identifies three positive regulatory regions that enhance LIN-28 expression, counteracting the negative effects of the let-7 and lin-4 microRNAs and the lep-5 long non-coding RNA.

Indexed as

Caenorhabditis elegansCaenorhabditis elegans ProteinsGene Expression Regulation, DevelopmentalRNA-Binding Proteins3' Untranslated RegionsAnimalsCRISPR-Cas SystemsMicroRNAsRepressor Proteins3' Untranslated RegionsCaenorhabditis elegans Proteinslet-7 microRNA, C elegansLIN-28 protein, C eleganslin-4 microRNA, C elegansMicroRNAsRepressor ProteinsRNA-Binding Proteins3′ UTRCaenorhabditis elegansDevelopmental timinglep-5lin-28microRNA

Identifiers

PMID42063341
PMCPMC13286352

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.